Skip to main content

Advertisement

SpringerLink
Log in

A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

The potential of radioimmunotherapy to selectively kill tumour cells is well established. However, optimisation is required with regards to increasing tumour localisation of antibodies. We used the PDGF-receptor inhibitor imatinib mesylate to improve tumour-specific antibody localisation in two models of colorectal adenocarcinoma and correlated antibody localisation with changes to tumour microvasculature. Mice bearing human colorectal xenografts (LS174T or SW1222) were treated with imatinib prior to administration of radiolabeled anti-CEA antibodies (125I-A5B7). Whole tumour and regional localisation of radiolabeled antibodies were measured. Microvessel density and pericyte coverage were quantified in whole tumours and correlated with 125I-A5B7 localisation. Imatinib increased uptake of 125I-A5B7 in LS174T but not SW1222 tumours after 48 h (p < 0.05). Imatinib reduced microvessel density in both models (p < 0.05) but reduced pericyte attachment to endothelial cells only in SW1222 xenografts (p < 0.05). Imatinib increases antibody distribution in LS174T tumours but not SW1222 tumours, and this correlated to changes in tumour microvessels. Accelerated clearance of radiolabeled antibody from normal tissues in both models resulted in enhanced tumour to normal tissue ratios. This improvement in tumour/normal tissue ratio has potential clinical benefit from a therapy and imaging perspective, and merits further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Fidarova EF, El-Emir E, Boxer GM, Qureshi U, Dearling JL, Robson MP, et al. Microdistribution of targeted, fluorescently labeled anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for radioimmunotherapy. Clin Cancer Res. 2008;14:2639–46.

    Article  PubMed  CAS  Google Scholar 

  2. Dancey G, Violet J, Malaroda A, Green AJ, Sharma SK, Francis R, et al. A phase I clinical trial of CHT-25 a 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res. 2009;15:7701–10.

    Article  PubMed  CAS  Google Scholar 

  3. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14:2577–90.

    Article  PubMed  Google Scholar 

  4. Dearling JL, Flynn AA, Qureshi U, Whiting S, Boxer GM, Green A, et al. Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. Nucl Med Biol. 2009;36:883–94.

    Article  PubMed  CAS  Google Scholar 

  5. El-Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, et al. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res. 2007;67:11896–905.

    Article  PubMed  CAS  Google Scholar 

  6. Flynn AA, Pedley RB, Green AJ, Boxer GM, Boden R, Bhatia J, et al. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. Int J Radiat Biol. 2002;78:407–15.

    Article  PubMed  CAS  Google Scholar 

  7. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001;61:4716–22.

    PubMed  CAS  Google Scholar 

  8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.

    Article  PubMed  CAS  Google Scholar 

  9. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure—an obstacle in cancer therapy. Nat Rev Cancer. 2004;4:806–13.

    Article  PubMed  CAS  Google Scholar 

  10. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731–6.

    Article  PubMed  CAS  Google Scholar 

  11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.

    Article  PubMed  CAS  Google Scholar 

  12. Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res. 2005;65:7824–31.

    PubMed  CAS  Google Scholar 

  13. Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, et al. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2003;9:6534–44.

    PubMed  CAS  Google Scholar 

  14. Vlahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, et al. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer. 2007;97:735–40.

    Article  PubMed  CAS  Google Scholar 

  15. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476–84.

    PubMed  CAS  Google Scholar 

  16. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res. 2004;10:897–908.

    Article  PubMed  CAS  Google Scholar 

  17. Vlahovic G, Rabbani ZN, Herndon JE, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer. 2006;95:1013–9.

    Article  PubMed  CAS  Google Scholar 

  18. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008;5:e19.

    Article  PubMed  Google Scholar 

  19. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24–40.

    Article  PubMed  CAS  Google Scholar 

  20. Folarin AA, Konerding MA, Timonen J, Nagl S, Pedley RB. Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. Microvasc Res. 2010;80:89–98.

    Article  PubMed  CAS  Google Scholar 

  21. Pedley RB, El-Emir E, Flynn AA, Boxer GM, Dearling J, Raleigh JA, et al. Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys. 2002;54:1524–31.

    Article  PubMed  CAS  Google Scholar 

  22. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555–77.

    Article  PubMed  CAS  Google Scholar 

  23. Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, et al. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin Cancer Res. 2009;15:4484–92.

    Article  PubMed  CAS  Google Scholar 

  24. Flynn AA, Green AJ, Boxer GM, Casey JL, Pedley RB, Begent RH. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys. 1999;43:183–9.

    Article  PubMed  CAS  Google Scholar 

  25. Ozerdem U, Monosov E, Stallcup WB. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res. 2002;63:129–34.

    Article  PubMed  CAS  Google Scholar 

  26. Barlow AL, Macleod A, Noppen S, Sanderson J, Guerin CJ. Colocalization analysis in fluorescence micrographs: verification of a more accurate calculation of Pearson's correlation coefficient. Microsc Microanal. 2010;16:710–24.

    Article  PubMed  CAS  Google Scholar 

  27. Baranowska-Kortylewicz J, Abe M, Nearman J, Enke CA. Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer. Clin Cancer Res. 2007;13:299–306.

    Article  PubMed  CAS  Google Scholar 

  28. Boucher Y, Lee I, Jain RK. Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res. 1995;50:175–82.

    Article  PubMed  CAS  Google Scholar 

  29. Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006;50:248–64.

    PubMed  CAS  Google Scholar 

  30. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Manuel Rodriguez-Justo for his assistance in the histopathological analysis.

Grant support

VSR is funded as part of the Comprehensive Cancer Imaging Centre funded by Cancer Research Campaign UK (CRUK), Department of Health (UK), Medical Research Council, UK and the Engineering and Physical Sciences Research Council, (MRC) UK. GB is funded by the MRC, UK and MR is funded by CRUK. RBP is funded by UCL.

Author information

Authors and Affiliations

  1. Department of Oncology, UCL Cancer Institute, Paul O’Gorman Building, University College London, London, WC1 6BT, UK

    Vineeth S. Rajkumar, Geoff Boxer, Mathew Robson & R. Barbara Pedley

  2. Department of Neuroscience, Royal Free and University College Medical School, University College London, London, NW3 2QG, UK

    John Muddle

  3. Department of Medical Physics, North Middlesex University Hospital Trust, London, N18 1QX, UK

    Yanni Papastavrou

Authors
  1. Vineeth S. Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoff Boxer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mathew Robson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Muddle
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanni Papastavrou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Barbara Pedley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vineeth S. Rajkumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajkumar, V.S., Boxer, G., Robson, M. et al. A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma. Tumor Biol. 33, 2019–2029 (2012). https://doi.org/10.1007/s13277-012-0461-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0461-9

Keywords

Search

Navigation